Simulations Plus, Inc. (SLP)

In the past six months, Simulations Plus, Inc. (SLP) stock has experienced a decline. The share price as of December 31, 2025, was $18.23, a decrease of 34.68% from January 2, 2025. The company reported disappointing fiscal Q1 2026 earnings, with adjusted earnings of $0.13 per share, missing analyst estimates by 27.8%, and revenue declining 3% year-over-year to $18.4 million due to a 17% plunge in software segment sales. The company also reported a year-over-year revenue decline of 6% in Q4 2025, despite a full-year increase of 13%. Despite these challenges, management reaffirmed its fiscal 2026 guidance.

Simulations Plus experiences normal seasonality patterns in its business. The first fiscal quarter is typically not the most robust quarter for software renewals, with peaks in renewals occurring in the second and third quarters. The company's software revenue flow generally follows these historical seasonality patterns. Additionally, the first part of the fiscal year may see reduced revenue contribution from Pro-ficiency platform software and Medical Communication service revenues compared to the prior year. Services demand is considered a leading indicator for software demand.

Simulations Plus, Inc. (SLP) is a provider in the biopharma sector, specializing in software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company operates through software and services segments, developing and licensing biosimulation and cheminformatics software, and offering consulting services to predict drug candidate behavior. Major products include GastroPlus, ADMET Predictor, MonolixSuite, DDDPlus and MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales products, MedChem Designer and MedChem Studio, and Pro-ficiency. The company's technology is licensed and utilized globally by pharmaceutical, biotechnology, and regulatory agencies.

Simulations Plus, Inc. is headquartered in Research Triangle Park, North Carolina, U.S. The company's technology is licensed and utilized worldwide, generating maximum revenue from the USA, followed by EMEA and Asia Pacific.

Simulations Plus has a "News Sentiment" score of 0.32, indicating a generally neutral to slightly positive sentiment in the news over the last 14 days. The company's focus on AI integration and cloud-based solutions, along with its role in accelerating drug discovery, development, and commercialization, suggests a positive perception within the biopharma industry.

Simulations Plus, Inc. has 371 institutional owners and shareholders holding a total of 21,606,891 shares. Approximately 78.08% of the stock is held by institutions, while 19.10% is held by insiders, and 33.24% by retail investors. Major institutional owners include Morgan Stanley, BlackRock, Inc., Tributary Capital Management, LLC, and Vanguard Group Inc. Walter Woltosz, the company's founder, owns the most shares of Simulations Plus (SLP) among individual investors.